pharmaphorum

JUNE 12, 2025

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Health and Personal Care Stores 59

Health and Personal Care Stores Pharmaceutical Companies Pharmaceutical Companies Insurance Coverage 59

STAT

JANUARY 15, 2025

billion in revenue by dispensing medicines to treat cancer, HIV, heart disease, and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022.  STAT later revealed that Biogen executives recruited an FDA official to help secure the approval. The

Insurance 105

Insurance FDA 105

The Checkup by Singlecare

JANUARY 15, 2025

Food and Drug Administration (FDA), such as Rybelsus (oral semaglutide), Mounjaro (tirzepatide), Zepbound (tirzepatide), and Saxenda (liraglutide). While a regular pharmacy dispenses commercially manufactured FDA-approved medications, compounding pharmacies prepare customized medications tailored to individual patient needs, says Eric F.

Compounding 98

Compounding Compounding Pharmacies FDA Dosage 98

The Checkup by Singlecare

NOVEMBER 26, 2024

A 2022 study found that both B12 and B5 had protective effects against COVID infection, while a 2020 study found that vitamin B12 (when combined with vitamin D and magnesium) improved outcomes for elderly patients hospitalized with COVID-19. Vitamin C: Vitamin C is well known for its positive effects on the immune system.

Immunization 94

Immunization Hospitals FDA 94

PharmaVoice

JUNE 6, 2025

The first one approved by the FDA — Mylotarg from Pfizer subsidiary Wyeth for acute leukemia — came to market in 2000. Now, 15 different molecules have been approved by the FDA. It wasn’t always a sure bet that ADCs would break through the noise, though. And the industry doesn’t always move on the right trends.

Chemotherapy 147

Chemotherapy FDA 147

Drug Topics

JULY 10, 2025

Daymon, 2022 Private Brand Intelligence Report, May 2023. Our team will be on site to share insights and showcase our portfolio of more than 500 health and wellness OTC products through the Foster & Thrive brand name, including affordable and eco-friendly offerings that reflect today’s consumer priorities. Fred Reichheld. April 2025.

Health and Personal Care Stores 247

Health and Personal Care Stores Independent Pharmacies Labelling Specialty Pharmacies 247

The Checkup by Singlecare

MARCH 11, 2025

Drug manufacturer Novo Nordisk produces it under the brand name Rybelsus , and the FDA approved it for managing blood glucose in people with Type 2 diabetes but not Type 1 diabetes. Some compounding pharmacies might make semaglutide tablets themselves, but these drugs arent FDA-approved or inspected. mg dose once weekly. at 12 months.

Compounding 52

Compounding Compounding Pharmacies FDA Dosage 52

IDStewardship

JUNE 19, 2025

In 2014, the US FDA approved this regimen, and it features in the latest WHO guidelines for LTBI treatment. The rifapentine group had higher treatment completion rates (82.1% versus 69%) than the isoniazid group, mirroring findings from U.S. TB Control Programs 21.

HIV Treatment and Prevention Agents 130

HIV Treatment and Prevention Agents Adverse Reactions Dosage Labelling 130

The Checkup by Singlecare

APRIL 18, 2025

In fact, its kind of a jack-of-all-trades drug, approved by the Food and Drug Administration (FDA) to treat epilepsy, postherpetic neuralgia, and restless leg syndrome. Its also prescribed off-label for other types of nerve pain, diabetic neuropathy, mood disorders, and alcohol use disorder.

Adverse Reactions 52

Adverse Reactions Controlled Substances Labelling Dosage 52

Pharmacy Times

JULY 12, 2025

December 2022. News release. Oregon Health and Science University. May 9, 2019. Accessed July 11, 2025. Arkansas Maternal Mortality Review Committee. Legislative Report. Accessed July 11, 2025. Koonin LM, Patel A. Timely antiviral administration during an influenza pandemic: key components. Am J Public Health. 2018;108(Suppl 3):S215-S220.

Independent Pharmacies 65

Independent Pharmacies Hospitals Compounding Pharmacies Immunization 65

Pharmacy Times

JUNE 23, 2025

Its average fiscal year 2022 readmission rate was 23.7%, exceeding the 19.6% The hospital-approved protocol, created in June 2022, granted TOC pharmacists prescribing authority for guideline-directed medical therapy (GDMT), consisting of a 30-day supply of rescue and triple-therapy inhalers, at discharge for patients with AECOPD.

Hospitals 65

Hospitals Compounding Pharmacies Vaccines Immunization 65

The Checkup by Singlecare

APRIL 15, 2025

Mounjaro (tirzepatide) is a brand-name prescription medication that is approved by the Food and Drug Administration (FDA) to improve blood sugar levels in people with Type 2 diabetes. The FDA recently approved generic versions of two other GLP-1s , Victoza (liraglutide) and Byetta (exenatide). Is there a generic for Mounjaro?

Compounding 85

Compounding Dosage Compounding Pharmacies FDA 85

Pharmacy Times

JULY 8, 2025

May 4, 2022. Isatuximab shows promise in enhancing PFS for patients with multiple myeloma. Pharmacy Times. August 8, 2024. Accessed July 8, 2025. Multiple myeloma. Cleveland Clinic. Accessed July 8, 2025.

Compounding Pharmacies 73

Compounding Pharmacies Immunization Specialty Pharmacies Compounding 73

Pharmacy Times

JUNE 23, 2025

The Orange Book is the reference, and it allows the FDA to declare something [to be] therapeutically equivalent. The FDA Approval Process Within the FDA approval process, the 505(b)(1) new drug application (NDA) submission pathway is the pathway by which new drugs are able to seek approval.

FDA 65

FDA Compounding Pharmacies Dosage Hospitals 65

PharmTech

JULY 4, 2025

While treatments for infection, inflammation, high eye pressure, and neovascularization have been shown to be effective, this method of delivery is considered “off-label,” as FDA has not approved products specifically for this use, except two intracameral implants (see below). Press Release, March 2, 2022. PLoS ONE 2011 6, e24513.

Dosage 64

Dosage FDA Vaccines Pharmaceutical Companies 64

The Checkup by Singlecare

MARCH 31, 2025

Ozempic is the brand name for semaglutide, which is a medication thats FDA approved to treat high blood sugar in people with Type 2 diabetes. One example of this is a meta-analysis published in Frontiers in Cardiovascular Medicine in 2022.

Dosage 52

Dosage Labelling Hospitals FDA 52

Pharmacy Times

JULY 9, 2025

1,2 To better understand this relationship, researchers assessed 4754 patients with CLL/SLL who were treated with either venetoclax and obinutuzumab from April 2016 to August 2022 (n = 2104) or zanubrutinib from November 2019 to August 2023 (n = 2650).

Immunization 65

Immunization Compounding Pharmacies Hospitals Specialty Pharmacies 65

Pharmacy Times

JULY 2, 2025

On February 21, 2020, the FDA approved eptinezumab-jjmr (Vyepti; Lundbeck) as the first intravenous migraine preventative treatment for adults. 1,3 REFERENCES FDA approves Lundbeck’s EPTINEZUMAB-JJMR™ (eptinezumab‑jjmr) — the first and only intravenous preventive treatment for migraine. News release. February 21, 2020. Subscribe Now!

Compounding Pharmacies 130

Compounding Pharmacies FDA Immunization Specialty Pharmacies 130

The Checkup by Singlecare

JUNE 25, 2025

Due to Ozempic’s newsworthy shortages and a growing demand for more GLP-1 drugs, people started talking about Mounjaro in 2022, when it was approved by the Food and Drug Administration (FDA) for the treatment of Type 2 diabetes. Mounjaro was approved by the FDA in 2022 for the treatment of Type 2 diabetes.

Insurance 52

Insurance Dosage FDA Labelling 52

Pharmacy Times

JUNE 19, 2025

2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. In October 2024, CAR T therapy axicabtagene ciloleucel (Yescarta; Kite Pharma) received FDA regenerative medicine advanced therapy designation as a first-line treatment for high-risk large B-cell lymphoma. Accessed February 2025. March 6, 2025.

Compounding 65

Compounding Compounding Pharmacies FDA Immunization 65

Pharmacy Times

JUNE 24, 2025

SHOW MORE Hulio shows comparable efficacy and safety to Humira in treating chronic plaque psoriasis, supporting its FDA interchangeability status. The authors noted that these results support the FDA-granted interchangeability status of Hulio. mL) with high-concentration Humira (40 mg/0.4 mL) with high-concentration Humira (40 mg/0.4

Compounding Pharmacies 50

Compounding Pharmacies FDA Immunization Hospitals 50

The Checkup by Singlecare

JUNE 24, 2025

The Food and Drug Administration (FDA) has approved certain opioids for: Relief of mild to moderate severe pain (e.g., The Food and Drug Administration (FDA) has approved certain opioids for: Relief of mild to moderate severe pain (e.g., StatPearls , 2024) Opioid overdose deaths made up 76% of all drug overdose deaths in 2022. (CDC,

FDA 52

FDA Compounding Insurance Hospitals 52

Pharmacy Times

JULY 10, 2025

Medication Adherence Requires Personalized Communication Alva emphasized that effective counseling about medications—especially those with intimidating FDA warnings—requires compassionate, patient-centered communication.

Specialty Pharmacies 65

Specialty Pharmacies Vaccines Immunization Compounding Pharmacies 65

Pharmaceutical Technology

JULY 4, 2025

Only 4% of global drugs sales will have patent protection, compared to 12% and 6% in 2022 and 2024. According to a Reuters article, pharma companies launched new US drugs at prices 35% higher in 2023, compared to those launched in 2022. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.

Chemotherapy 52

Chemotherapy Packaging Communication Hospitals 52

Pharmacy Times

JUNE 17, 2025

OTC Use Saves Billions From Cost-Effective Products and Encounters Image credit: Amina | stock.adobe.com A 2022 publication purported $167 billion in savings in ancillary health care cost avoidance through the widespread use of OTC products in the United States. November 2022. REFERENCES The power of OTCs to provide consumer value.

Compounding Pharmacies 132

Compounding Pharmacies Drug Utilization Review Immunization Hospitals 132

Pharmacy Times

JUNE 23, 2025

1 Image credit: Cynthia | stock.adobe.com The discussion featured Vivian Fonseca, MD, of the Tulane University School of Medicine, who presented an overview of tirzepatide based on the FDA-approved label and clinical guidelines. FDA Approves Tirzepatide Injection for Adults With Type 2 Diabetes. May 16, 2022. Pharmacy Times.

HIV Treatment and Prevention Agents 81

HIV Treatment and Prevention Agents Compounding Pharmacies Immunization FDA 81

The Checkup by Singlecare

JUNE 25, 2025

In 2021, the Food and Drug Administration (FDA) approved Wegovy for weight loss in adults with obesity—or who are overweight with at least one weight-related health condition. In 2022, the approval was expanded to include eligible individuals 12 years and older with obesity. Of those, 34% were adult males and 28% were adult females.

Insurance Coverage 52

Insurance Coverage Insurance FDA Labelling 52

Pharmacy Times

JUNE 30, 2025

Updated October 6, 2022. FDA approves ropeginterferon alfa-2b-njft for polycythemia vera. REFERENCES 1. Ropeginterferon alfa 2b for early myelofibrosis. Accessed June 30, 2025. ASCO 2025 delivers insights into future of myelofibrosis care. Pharmacy Times. June 3, 2025. Accessed June 30, 2025. November 12, 2021.

Compounding Pharmacies 86

Compounding Pharmacies Immunization Hospitals Compounding 86

The Checkup by Singlecare

JULY 15, 2025

The Food and Drug Administration (FDA) may no longer approve the drug based on new safety evidence. Changes in GLP-1 insurance coverage may be due to the rising costs to health plans of the medication and the recent FDA approval of generic versions of Victoza ( liraglutide ) and Byetta ( exenatide ). Contact your insurance company.

Insurance 52

Insurance Insurance Coverage Documentation Health Insurance Companies 52

pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 78

Pharmaceutical Companies Pharmaceutical Companies FDA Immunization 78

The FDA Law Blog

JANUARY 5, 2025

Livornese As promised in the Fall Unified Regulatory Agenda, FDA issued the final rule to establish the pathway to obtain marketing approval of a nonprescription drug product with an additional condition for nonprescription use (ACNU) on December 26, 2024, before the end of the calendar year. 105288 (Dec.

Labelling 59

Labelling FDA 59

Pharmacy Times

JULY 14, 2025

SHOW MORE FDA fast-tracks TRE-515 for advanced prostate cancer, combining it with radiation therapy to enhance treatment outcomes and patient care. The FDA has granted fast track designation to TRE-515 (Trethera Corporation), a novel drug, in combination with radiation therapy for the treatment of prostate cancer.

FDA 73

FDA Compounding Pharmacies Compounding Immunization 73

The FDA Law Blog

JUNE 3, 2025

The assertion that prescribing immediate-release opioids longer than two or three months is a red flag may have originated with the Center for Disease Control and Prevention (CDC) 2022 Clinical Practice Guideline for Prescribing Opioids for Pain. Deborah Dowell et al., 1, Recommendation 3. Recommendation 1.

Prescription Filling 59

Prescription Filling Controlled Substances 59

PharmTech

JUNE 24, 2025

In May 2024, the US Food and Drug Administration (FDA) approved Moderna’s next-generation base-modified mRNA-lipid nanoparticle (LNP) respiratory syncytial virus (RSV) vaccine mRESVIA (mRNA-1345) in adults aged 60 years and older with lower respiratory tract disease (5). Pfizer’s COVID-19 Vaccine Secures First Full FDA Approval.

Vaccines 59

Vaccines Dosage FDA Immunization 59

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA Communication 52

The Checkup by Singlecare

JULY 3, 2025

Wegovy (semaglutide) is a prescription medication that’s approved by the Food and Drug Administration (FDA) to help with weight management in people ages 12 years and older with obesity and in adults who are overweight with at least one weight-related comorbid condition.

Insurance 52

Insurance Packaging FDA Labelling 52

The Checkup by Singlecare

JULY 8, 2025

2017) In 2022 alone, there were an estimated 534,890 people in the U.S. using Linzess ( ClinCalc , 2022) By 2024, more than 5 million people had been prescribed Linzess since its approval. 2025) From 2022 to 2023, Linzess saw an increase in prescription demand of 10%. million unique patients. Ironwood Pharmaceutical Inc.

Insurance 52

Insurance FDA Dosage 52